Literature DB >> 16818761

CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism.

John J Engelhardt1, Timothy J Sullivan, James P Allison.   

Abstract

CTLA-4 has been shown to be an important negative regulator of T cell activation. To better understand its inhibitory action, we constructed CTLA-4 transgenic mice that display constitutive cell surface expression of CTLA-4 on CD4 and CD8 T cells. In both in vivo and in vitro T cell responses, CTLA-4 overexpression inhibits T cell activation. This inhibition is dependent on B7 and CD28, suggesting that overexpressed CTLA-4 inhibits responses by competing with CD28 for B7 binding or by interfering with CD28 signaling. In addition, expression of the transgene decreases the number of CD25+Foxp3+ T cells in these mice, but does not affect their suppressive ability. Our data confirm the activity of CTLA-4 as a negative regulator of T cell activation and that its action may be by multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818761     DOI: 10.4049/jimmunol.177.2.1052

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

Review 1.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 2.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.

Authors:  Jillian H Hurst
Journal:  J Clin Invest       Date:  2015-09-08       Impact factor: 14.808

Review 4.  Whole cell vaccines--past progress and future strategies.

Authors:  Bridget P Keenan; Elizabeth M Jaffee
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

5.  Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.

Authors:  Spencer C Wei; Roshan Sharma; Nana-Ama A S Anang; Jacob H Levine; Yang Zhao; James J Mancuso; Manu Setty; Padmanee Sharma; Jing Wang; Dana Pe'er; James P Allison
Journal:  Immunity       Date:  2019-03-26       Impact factor: 31.745

Review 6.  Immune microenvironments in solid tumors: new targets for therapy.

Authors:  Stephen L Shiao; A Preethi Ganesan; Hope S Rugo; Lisa M Coussens
Journal:  Genes Dev       Date:  2011-12-15       Impact factor: 11.361

Review 7.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 8.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis.

Authors:  Ying Ma; Bi-rong Lin; Bei Lin; Sheng Hou; Wei-zhu Qian; Jing Li; Min Tan; Jian Ma; Bo-hua Li; Hao Wang; Ai-dong Wen; Ya-jun Guo
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

10.  Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.

Authors:  Fabian Flores-Borja; Elizabeth C Jury; Claudia Mauri; Michael R Ehrenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.